Mutual of America Capital Management LLC Sells 1,781 Shares of Amgen Inc. (NASDAQ:AMGN)

Mutual of America Capital Management LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 2.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 64,535 shares of the medical research company’s stock after selling 1,781 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Amgen were worth $16,820,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in AMGN. AMF Tjanstepension AB increased its stake in Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after acquiring an additional 17,387 shares during the last quarter. Swedbank AB increased its stake in Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after acquiring an additional 5,751 shares during the last quarter. Goldstone Financial Group LLC bought a new stake in shares of Amgen during the third quarter worth $253,000. Baron Silver Stevens Financial Advisors LLC grew its stake in shares of Amgen by 11.5% during the third quarter. Baron Silver Stevens Financial Advisors LLC now owns 755 shares of the medical research company’s stock worth $243,000 after buying an additional 78 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Amgen by 8.9% during the third quarter. Principal Securities Inc. now owns 13,501 shares of the medical research company’s stock worth $4,350,000 after buying an additional 1,104 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

AMGN stock opened at $308.06 on Friday. The firm has a market cap of $165.49 billion, a price-to-earnings ratio of 40.80, a PEG ratio of 2.63 and a beta of 0.56. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company’s fifty day simple moving average is $280.87 and its 200 day simple moving average is $300.16.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.09%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is currently 126.09%.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Truist Financial decreased their target price on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Amgen in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, Bank of America boosted their target price on shares of Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a research note on Thursday, February 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $314.09.

Insider Activity

In other news, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. Company insiders own 0.69% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.